NCT01276704View on ClinicalTrials.gov

Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Breast Cancer
Interventions
DRUG

Placebo

The placebo contains same filler materials as commercially available Brevail® but without active SDG.

DRUG

secoisolariciresinol

1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg

Trial Locations (7)

43210

Ohio State Unviersity Medical Center, Columbus

60611

Northwestern University Medical Center, Chicago

66160

University of Kansas Medical Center, Kansas City

72205

University of Arkansas for Medical Sciences, Little Rock

73104

University of Oklahoma Health Sciences Center, Oklahoma City

02215

Dana Farber Cancer Institute, Boston

98109-1023

University of Washington, Seattle

Sponsors

Collaborators (1)

Lignan Research Inc.
All Listed Sponsors
collaborator

Lignan Research Inc.

INDUSTRY

lead

Carol Fabian, MD

OTHER